Multicenter phase II trial of vitamin K2 monotherapy and vitamin K2 plus 1α-hydroxyvitamin D3 combination therapy for low-risk myelodysplastic syndromes

Leukemia Research

Volumn 34, Issue 9, 2010, Pages 1151-1157

  Akiyama, Nobu ^a,g   Miyazawa, Keisuke ^b   Kanda, Yoshinobu ^c,g   Tohyama, Kaoru ^d,h   Omine, Mitsuhiro ^e,i   Mitani, Kinuko ^f,g,h   Ohyashiki, Kazuma ^b,g,h  

^a TEIKYO UNIVERSITY   (Japan)

^b Tokyo Medical University   (Japan)

^c JICHI MEDICAL UNIVERSITY   (Japan)

^d KAWASAKI MEDICAL SCHOOL   (Japan)

^e SHOWA UNIVERSITY   (Japan)

^f DOKKYO MEDICAL UNIVERSITY   (Japan)

^g Japan Hematology Oncology Clinical Study Group (J HOCS)   (Japan)

^h Japanese Research Committee for Research on Epoch making Therapy for Myelodysplastic Syndrome   (Japan)

ⁱ Japanese Research Committee for Measures for Intractable Diseases   (Japan)

Author keywords

Myelodysplastic syndromes; Vitamin D3; Vitamin K2

Indexed keywords

ALFACALCIDOL; HEMOGLOBIN; MENATETRENONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOPENIA; DRUG RESPONSE; DRUG WITHDRAWAL; DYSPLASIA; FEMALE; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LOWER ABDOMINAL PAIN; MALE; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; PANCYTOPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; STOMACH DISEASE; THROMBOCYTOPENIA;

EID: 77955281503     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.04.006     Document Type: Article

References (41)

1. Steensma D.P., Bennett J.M. The myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc 2006, 81:104-130.
2. Greenberg P.L., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
3. National comprehensive cancer network NCCN clinical practice guidelines in oncology. Myelodysplastic syndromes V.2.2010 2010, Available at (http://www.nccn.org/professionals/physician_gls/PDF/mds.pdf).
4. Kasner M.T., Luger S.M. Update on the therapy for myelodysplastic syndrome. Am J Hematol 2009, 84:177-186.
5. Orimo H., Shiraki M., Tomita A., Morii H., Fujita T., Ohata M., et al. Effect of menatetrenone on the bone and calcium metabolism in osteoporosis. a double-blind placebo-controlled study. J Bone Miner Metab 1998, 16:106-112.
6. Sasaki N., Kusano H., Takahashi H., Ando Y., Yano K., Tsuda E., et al. Vitamin K2 (menatetrenone) effectively prevents fractures and sustains number bone mineral density in osteoprotegerin (OPG). J Bone Miner Metab 2005, 23:41-47.
7. Takami A., Nakao S., Ontachi Y., Yamauchi H., Matsuda T. Successful therapy of myelodysplastic syndrome with menatetrenone, a vitamin K2 analog. Int J Hematol 1999, 69:24-26.
8. Miyazawa K., Nishimaki J., Ohyashiki K., Enomoto S., Kuriya S., Fukuda R., et al. Vitamin K2 therapy for myelodysplastic syndromes (MDS) and post-MDS acute myeloid leukemia: information through a questionnaire survey of multi-center pilot studies in Japan. Leukemia 2000, 14:1156-1157.
9. Abe Y., Muta K., Hirase N., Choi I., Matsushima T., Hara K., et al. Vitamin K2 therapy for myelodysplastic syndrome. Rinsho Ketsueki 2002, 43:117-121. [Japanese].
10. Takami A., Asakura H., Nakao S., Menatetrenone A vitamin K2 analog, ameliorates cytopenia in patients with refractory anemia of myelodysplastic syndrome. Ann Hematol 2002, 81:16-19.
11. Yaguchi M., Miyazawa K., Katagiri T., Nishimaki J., Kizaki M., Tohyama K., et al. Vitamin K2 and its derivatives induce apoptosis in leukemia cells and enhance the effect of all-trans retinoic acid. Leukemia 1997, 11:779-787.
12. Nishimaki J., Miyazawa K., Yaguchi M., Katagiri T., Kawanishi Y., Toyama K., et al. Vitamin K2 induces apoptosis of a novel cell lines established from a patient with myelodysplastic syndrome in blastic transformation. Leukemia 1999, 13:1399-1405.
13. Miyazawa K., Yaguchi M., Funato K., Gotoh A., Kawanishi Y., Nishizawa Y., et al. Apoptosis/differentiation-inducing effects of vitamin K2 on HL-60 cells: dichotomous nature of vitamin K2 in leukemia cells. Leukemia 2001, 15:1111-1117.
14. Miyazawa K., Aizawa S. Vitamin K2 improves the hematopoietic supportive functions of bone marrow stromal cells in vitro: a possible mechanism of improvement of cytopenia for refractory anemia in response to vitamin K2 therapy. Stem Cells Dev 2004, 13:449-451.
15. 3. Proc Natl Acad Sci USA 1981, 78:4990-4995.
16. Koefler H.P., Hirji K., Itru L. 1,25-dihydroxyvitamin D3, in vivo and in vitro effects on human preluekemic and leukemic cells. Cancer Treat Rep 1985, 69:1389-1407.
17. Mehta A.B., Kumaran T.O., Marsh G.W. Treatment of advanced myelodysplastic syndrome with alfacalcidol. Lancet 1984, ii:761.
18. Mellibovsky L., Díez A., Pérez-Vila E., Serrano S., Nacher M., Aubía J., et al. Vitamin D treatment in myelodysplastic syndromes. Br J Haematol 1998, 100:516-520.
19. Motomura S., Kanamori H., Maruta A., Kodama F., Ohkubo T. The effect of 1-hydroxyvitamin D3 for prolongation of leukemic transformation-free survival in myelodysplastic syndromes. Am J Hematol 1991, 38:67-68.
20. Rchird C., Mazo E., Cuadrado M.A., Iriondo A., Bello C., Gandarrillas M.A., et al. Treatment with myelodysplastic syndrome with 1,25-hydoxy-vitamin D3. Am J Hematol 1986, 23:175-178.
21. Yoshida Y., Oguma S., Uchino H., Maekawa T., Nomura T. A randomized study of alfacaldicol in refractory myelodysplastic anaemas. A Japanese cooperative study. Int J Clin Pharm Res 1993, 13:21-27.
22. Funato K., Miyazawa K., Yaguchi M., Gotoh A., Ohyashiki K. Combination of 22-oxa-1,25-dihyroxyvitamin D3, a vitamin D3 derivative, with vitamin K2 (VK2) synergistically enhances cell differentiation but suppresses VK2-inducing apoptosis in HL-60 cells. Leukemia 2002, 16:1519-1527.
23. CIP1. Int J Oncol 2005, 27:893-900.
24. Brunning R.D., Bennet J.M., Flandrin G., Matutes E., Head D., Vardiman J.W., et al. Myelodysplastic syndromes. WHO classification of tumors. pathology and genetics of tumors of haematopoietic and lymphoid tissues 2001, 61-74. IARC Press, Lyon. E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (Eds.).
25. Cheson B.D., Bennet J.M., Kantarjian H., Pinto A., Schiffer C.A., Nimer S.D., et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000, 96:3671-3674.
26. Oken M.M., Creech R.H., Tormey D.C., Horton J., Davis T.E., McFadden E.T., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5:649-655.
27. Yaguchi M., Miyazawa K., Otawa M., Katagiri T., Nishimaki J., Uchida Y., et al. Vitamin K2 selectively induces apoptosis of blastic cells in myelodysplastic syndrome: flow cytometric detection of apoptotic cells using APO2.7 monoclonal antibody. Leukemia 1998, 12:1392-1397.
28. Takahashi T., Ichiba S., Okuno Y., Sugiyama H., Sakai Y., Imura H., et al. Therapeutic effectiveness of vitamin D3 in patients with myelodysplastic syndromes, leukemia and myeloproliferative disorders. Rinsho Ketsueki 1989, 30:1-10.
29. Kizaki M., Koeffler H.P. Differentiation-inducing agents in the treatment of myelodysplastic syndromes. Semin Oncol 1992, 19:95-105.
30. Yokoyama T., Miyazawa K., Naito M., Toyotake J., Tauchi T., Itoh M., et al. Vitamin K2 induces autophagy and apoptosis simultaneously in leukemia cells. Autophagy 2008, 4:629-640.
31. Enomoto M., Tsuchida A., Miyazawa K., Yokoyama T., Kawakita H., Tokita H., et al. Vitamin K2-induced cell growth inhibition via autophagy formation in cholangiocellular carcinoma cell lines. Int J Mol Med 2007, 20:801-808.
32. Kawakita H., Tsuchida A., Miyazawa K., Naito M., Shigoka M., Kyo B., et al. Growth inhibitory effects of vitamin K2 on colon cancer cell lines via different types of cell death including autophagy and apoptosis. Int J Mol Med 2009, 23:709-716.
33. Wang J., Lian H., Zhao Y., Kauss M.A., Spindel S. Vitamin D3 induces autophagy of human myeloid leukemia cells. J Biol Chem 2008, 283:25596-25605.
34. Kirkin V., McEwan D.G., Novak I., Dikic I. A role for ubiquitin in selective autophagy. Mol Cell 2009, 34:259-269.
35. Levine B., Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008, 132:27-42.
36. Houwerzijl E.J., Pol H.W., Blom N.R., van der Want J.J., de Wolf J.T., et al. Erythroid precursors from patients with low-risk myelodysplasia demonstrate ultrastructural features of enhanced autophagy of mitochondria. Leukemia 2009, 23:886-891.
37. Yu L., Strandberg L., Lenardo M.J. The selectivity of autophagy and its role in cell death and survival. Autophagy 2008, 4:567-573.
38. Tsukamoto N., Mastushima T., Nojima M., Karasawa M., Murakami H., Sakuraya M., et al. Therapeutic result of vitamin K2 therapy in myelodysplastic syndrome. J Jpn Society Int Med 2001, 90:280. (abst. Japanese).
39. Imamura T., Ostuka E., Ogata M., Ogata Y., Kouno K., Uno N., et al. Clinical trial: Effectiveness of vitamin K2 for the treatment of MDS patients. Hematology Frontier 2005, 15:1858-1863. (Japanese).
40. Yoshinaga K., Teramura M., Hida M., Masuda M., Motoji T., Mizoguchi H. Therapeutic outcome of vitamin K2therapy in myelodysplastic syndromes. Rinsho Ketsueki 2002, 44:878. (abst. Japanese).
41. Tsurumi A., Kasahara C., Hara T., Yamada T., Sawada M., Ohyama M., et al. Combination therapy consisted of vitamin B6, vitamin D3 and vitamin K2 for myelodysplastic syndromes. Rinsho Ketsueki 2004, 46:765. (abst. Japanese).